In general, the dosage regimens based on rHSA/G-CSF 1500 μg have comparable efficacy and safety profiles with rhG-CSF, which tended to be the recommended preventive management for serious neutropenia, especially following anthracycline-containing chemotherapy, in clinical practice. The gene discussed is CSF3; the disease is neutropenia.